Integrated Multi-Testing for TB Care: Can One Patient Visit Detect More Diseases?

integrated multi-testing for TB

Search intent: Informational — readers want to understand whether India’s existing TB diagnostic infrastructure can be used to detect other diseases during the same patient visit, how integrated testing could improve healthcare access, and what limitations remain.

Related keywords: TB diagnosis in India, tuberculosis diagnostic infrastructure, integrated disease screening, multiplex diagnostic testing, one-stop healthcare screening, TB molecular testing, point-of-care testing, NTEP diagnostics, multi-disease testing

India’s tuberculosis response has spent years building something that is easy to overlook: a large diagnostic network capable of moving samples, performing molecular tests and connecting patients to treatment. The next question is whether that infrastructure can do more than detect tuberculosis.

Experts increasingly see an opportunity to use existing TB diagnostic touchpoints for integrated multi-testing for TB and other clinically relevant conditions. Instead of asking a patient to return multiple times for different investigations, healthcare facilities could potentially offer additional, appropriate tests during the same encounter when symptoms, age, risk factors or clinical circumstances justify them.

The idea is not as futuristic as it may sound. In 2026, international TB diagnostic recommendations have moved towards bringing molecular testing closer to primary-care and community settings, while new diagnostic platforms are increasingly being designed with broader testing capabilities in mind. India has also expanded technologies such as molecular TB testing, digital chest imaging and decentralised sample collection.

But there is an important distinction between integrating several tests into one healthcare visit and having a single specimen automatically test for every disease. The first is increasingly practical. The second remains technically, clinically and operationally challenging.

That distinction could shape the next stage of India’s TB elimination strategy.

Why TB infrastructure creates an opportunity for broader testing

TB diagnosis requires more than simply owning a laboratory machine. A functioning diagnostic system needs trained personnel, sample collection, transportation, laboratory quality systems, reporting mechanisms and a pathway connecting positive results to treatment.

India’s TB programme has developed these components over time through the National Tuberculosis Elimination Programme and associated public-health infrastructure.

That creates an unusual opportunity. A patient arriving at a facility because of persistent cough, fever, weight loss or another respiratory complaint may already be interacting with a system capable of collecting specimens, performing molecular testing or arranging imaging.

The question becomes: what other clinically relevant conditions can reasonably be assessed during that same encounter?

This is a very different approach from indiscriminate testing. The goal would not be to test every patient for everything. Instead, the system could use the existing visit as an opportunity to identify additional health problems when there is a clear clinical or public-health reason to do so.

What does integrated multi-testing actually mean?

Integrated testing can describe several different models, and confusing them can lead to unrealistic expectations.

This distinction is perhaps the most important part of the discussion.

When experts talk about making a TB visit more productive, they do not necessarily mean that a single tube of sputum should become a universal diagnostic sample. In many cases, the more realistic opportunity is to coordinate several appropriate investigations around the same patient encounter.

The “one visit” idea may be more important than the “one sample” idea

Healthcare systems often focus on the technology of testing, but patients experience healthcare through journeys.

A person may have to travel to a facility, wait for registration, meet a healthcare worker, provide a sample, undergo imaging and return later for results. If another health problem requires a separate visit, the cost is not merely financial. It can include lost wages, transport expenses, waiting time and the possibility that the patient simply does not return.

This is especially relevant in rural and underserved communities.

For such patients, one coordinated visit can sometimes be more valuable than one revolutionary machine.

That makes integrated TB services potentially powerful. A TB diagnostic encounter could become a gateway for targeted screening for other respiratory conditions, HIV where appropriate, diabetes or other relevant health risks, depending on programme design and informed clinical decision-making.

Why TB is a logical starting point

TB often intersects with other health problems rather than existing in isolation.

Patients with respiratory symptoms may have tuberculosis, chronic obstructive pulmonary disease, asthma, post-TB lung disease, bacterial infections or other conditions with overlapping symptoms. A person diagnosed with TB may also have medical or social factors that affect treatment outcomes and overall health.

That makes a purely disease-specific model less efficient in some settings.

Recent work on integrating TB and broader lung-health services in India has highlighted the overlap between tuberculosis and chronic respiratory diseases. The opportunity is therefore not simply to attach unrelated tests to a TB programme. It is to recognise that the same patient may need several connected forms of care.

India already has building blocks for this approach

India does not have to start from zero.

The country has developed extensive TB diagnostic capabilities, including molecular testing platforms such as CBNAAT and TrueNat, chest imaging initiatives and sample-transport networks designed to connect peripheral facilities with testing centres.

Recent innovations have also focused on taking diagnosis closer to patients. Newer near-point-of-care molecular approaches, for example, are designed to make TB testing possible in lower-level healthcare settings than was previously practical.

This decentralisation matters for integrated testing because a multi-disease strategy is only useful if patients can actually access the platform.

A sophisticated diagnostic centre in a major city can run many tests. The bigger public-health opportunity lies in determining which combinations can be delivered reliably at primary-healthcare and community levels.

The diagnostic network could become a “health gateway”

This is the unique opportunity that deserves more attention.

India’s TB infrastructure should not necessarily be viewed only as a network for finding tuberculosis. It could increasingly function as a health gateway for people who might otherwise have limited contact with formal healthcare.

Imagine a patient visiting a primary-care facility because of a persistent cough. Instead of treating the encounter as a single TB question, the healthcare worker could follow a structured pathway:

• Assess symptoms and TB risk.
• Conduct appropriate TB testing.
• Review relevant chronic-disease risk factors.
• Offer additional testing when clinically indicated.
• Use imaging or other investigations where appropriate.
• Connect abnormal findings to follow-up care.

This model does not require every patient to undergo a huge panel of tests. It requires the health system to make better use of the opportunity created by the patient’s presence.

Why “test everything” would be the wrong approach

There is an understandable temptation to interpret integrated testing as a reason to add as many tests as possible. That would be a mistake.

Every additional test has consequences. It requires money, equipment, quality control, trained staff and interpretation. More importantly, testing can produce false-positive or uncertain results that may lead to unnecessary anxiety and additional investigations.

Good screening is therefore targeted.

The best integrated model would ask a simple question before adding a test: Will the result meaningfully change what happens to this patient?

If the answer is no, testing may simply create more workload without improving care.

Where multiplex testing could make a difference

Multiplex technologies are particularly interesting because they can detect multiple targets using a single platform or assay. This can potentially reduce the number of separate laboratory steps needed for selected combinations.

However, multiplexing is easiest when diseases have compatible biological targets, sample types and testing requirements.

TB is caused by a specific bacterial organism, while many other diseases have completely different biological signatures. A test designed around TB nucleic acid does not automatically become useful for detecting unrelated conditions.

This is why the dream of a universal sample containing answers to every health question remains distant.

The future is more likely to involve purpose-built combinations: platforms capable of detecting a small number of clinically related conditions, supported by separate tests where necessary.

New TB testing technologies could accelerate the shift

Global diagnostic policy is already moving towards more accessible TB testing.

Recent recommendations have included near-point-of-care molecular tests, easier specimen collection approaches such as tongue swabs for people unable to produce sputum, and strategies intended to improve testing efficiency.

These developments are important because diagnostic decentralisation changes the economics of healthcare. If reliable testing can move closer to the patient, there may be more opportunities to combine services around the same encounter.

Newer diagnostic devices are also increasingly being designed with broader potential applications. Some platforms can potentially be adapted to detect conditions beyond TB, although each additional disease requires its own clinical validation and regulatory pathway.

That last point is crucial. Technical capability is not the same thing as clinical readiness.

What about HIV and other infections?

TB and HIV have a well-established clinical relationship, particularly because HIV can increase the risk of developing active TB. Where national or local clinical protocols recommend testing, integrating appropriate HIV services with TB care can reduce fragmentation.

The principle can extend beyond HIV. Depending on the patient population and local disease burden, integrated care could involve selected tests for other infections or chronic diseases.

But each combination needs to be evaluated independently. A test that makes sense in a TB clinic serving one population may not be appropriate in another setting.

The chronic-disease opportunity is even bigger

One of the most promising long-term possibilities may lie outside infectious diseases.

Patients seeking care for TB symptoms may also have undiagnosed diabetes, hypertension, anaemia or chronic respiratory disease. Some of these conditions can influence vulnerability to infection, treatment outcomes or long-term health.

This suggests a broader concept: TB clinics could become entry points into integrated primary healthcare.

The benefit would extend beyond TB detection. A person who comes to the health system for one problem could leave with a clearer understanding of several relevant health risks and a pathway for follow-up.

However, this should be done without weakening the core TB programme. If additional services overload staff or delay TB diagnosis and treatment, integration could become counterproductive.

The biggest bottleneck may not be the machine

Discussions about multi-testing often focus on diagnostic devices. Yet the real bottleneck may be everything around the machine.

Consider a rural facility with a sophisticated test. The platform may be capable of processing several targets, but the facility still needs electricity, trained operators, consumables, calibration, quality assurance, sample-management systems and reliable reporting.

Then comes the most important step: what happens after an abnormal result?

A test that identifies disease without a functioning referral pathway has limited public-health value.

This means India’s integrated-testing strategy should be designed around the entire care pathway rather than the laboratory alone.

One sample does not always mean one answer

There is another technical challenge that deserves attention: different diseases often require different biological samples.

TB may be investigated using respiratory specimens or, in selected circumstances, other samples. Blood tests are needed for many systemic conditions. Urine, stool or swabs may be more appropriate for other diseases.

Therefore, even if multiple diseases are assessed during a single visit, that does not necessarily mean one specimen can answer every question.

This is why the phrase “one visit, multiple relevant tests” may be a more realistic near-term goal than “one sample, every disease.”

Integrated testing versus traditional fragmented care

The integrated model does not eliminate specialised disease programmes. Instead, it creates a layer of coordination between them.

What could this mean for rural India?

The potential benefits are greatest where healthcare access is difficult.

For an urban patient living close to several diagnostic centres, an additional appointment may be inconvenient. For a rural worker who must travel a long distance, every additional visit can become a serious barrier.

India’s experience with decentralised TB sample collection and newer transport approaches demonstrates why access matters as much as laboratory accuracy.

Integrated services could therefore reduce missed opportunities: when a patient has already overcome the barrier of reaching a healthcare facility, the system can address more of the patient’s relevant health needs during that interaction.

The risk of overburdening TB services

Integration also has a downside if implemented poorly.

TB programmes have a specific mission: finding patients, confirming diagnosis, initiating treatment and preventing transmission. Adding too many unrelated services could stretch staff and dilute attention.

The solution is not to avoid integration but to design it carefully.

Services should be selected according to disease burden, patient risk, staff capacity and the likelihood that results will lead to meaningful care.

A small number of high-value additions may ultimately produce more benefit than an enormous diagnostic menu.

What India should prioritise next

A practical roadmap for integrated multi-testing could focus on five priorities.

• Map existing capacity: Identify which TB diagnostic sites already have the equipment, personnel and connectivity needed for additional testing.
• Choose high-value combinations: Prioritise diseases with strong clinical links to TB or significant relevance to the populations being served.
• Standardise referral: Ensure every additional test has a clear pathway for confirmation and treatment.
• Protect TB performance: Integration should not slow TB diagnosis or treatment initiation.
• Measure outcomes: Evaluate whether integrated testing actually increases case detection, reduces repeat visits and improves patient outcomes.

The future: from disease-specific programmes to connected diagnostics

The most important change may be conceptual rather than technological.

Public-health systems have traditionally been organised around individual diseases because each disease has different biology, treatment and control strategies. That approach remains necessary, but patients do not arrive divided into disease categories.

A person may have TB and diabetes. Another may have TB and HIV. Another may have post-TB lung disease years after treatment. A fourth may have symptoms that initially resemble TB but ultimately point to another respiratory condition.

The healthcare system therefore needs both specialised programmes and a mechanism for seeing the whole patient.

India’s TB diagnostic network could provide part of that bridge.

Prediction: “one visit, multiple answers” is more likely than a universal test

The most realistic near-term future is unlikely to be a magical cartridge that diagnoses every disease from one sample.

Instead, diagnostic systems are more likely to become modular. A single visit could involve a combination of molecular testing, imaging, blood tests and other investigations, with the exact package selected according to symptoms and risk.

Some platforms may eventually combine several targets, but clinical validation, affordability, regulation and laboratory quality will determine how widely they can be used.

In other words, the future of integrated diagnostics may be less about inventing one machine that does everything and more about making existing machines work together intelligently.

Conclusion: India’s TB network could become more than a TB network

The idea of integrated multi-testing for TB offers India a potentially powerful way to get more value from diagnostic infrastructure it has already built.

The immediate opportunity is not necessarily a universal “one sample, multiple diseases” test. A more achievable strategy is to coordinate relevant testing during a single patient visit, particularly where TB clinics and diagnostic centres already serve as important entry points into the health system.

That could mean combining TB diagnosis with selected respiratory, infectious-disease or chronic-disease assessments when clinically appropriate. The benefits could include fewer repeat visits, earlier identification of additional illnesses and better use of existing laboratory and diagnostic capacity.

But integration must be disciplined. Every additional test needs a clinical purpose, reliable quality control and a pathway to treatment. Otherwise, more testing could simply produce more results without better healthcare.

The real opportunity is therefore not to turn every TB clinic into a laboratory for every disease. It is to transform a disease-specific encounter into a smarter, patient-centred healthcare interaction.

India may not yet have a universal one-sample test for multiple diseases, but it already has something nearly as important: a diagnostic network that could potentially be connected more intelligently.

Four key takeaways

• India’s existing TB diagnostic infrastructure could potentially support targeted testing for other relevant health conditions during the same patient visit.
• “One visit, multiple relevant tests” is currently a more realistic goal than a universal test that detects every disease from one sample.
• Integrated testing could be particularly valuable for rural and underserved patients who face significant travel and access barriers.
• The success of multi-testing will depend not only on technology but also on quality control, clinical relevance, referral systems and follow-up care.

Frequently Asked Questions

What is integrated multi-testing for TB?

Integrated multi-testing means coordinating TB diagnosis with other clinically relevant investigations during the same healthcare encounter, rather than treating every disease as a completely separate diagnostic pathway.

Can one sample detect multiple diseases?

In some specific diagnostic systems, one specimen can be used to test for more than one target. However, there is currently no universal clinical test that can reliably diagnose all major diseases from one sample.

Why is one-visit testing important in India?

Reducing the number of healthcare visits can be particularly valuable for people in rural or underserved areas who may face travel costs, lost working time and limited access to diagnostic facilities.

Could TB clinics test for other diseases?

Potentially, yes. Where clinically appropriate, TB diagnostic encounters could be linked with selected tests for conditions that commonly overlap with TB or are relevant to the patient’s risk profile.

Would integrated testing replace TB-specific diagnostics?

No. TB-specific testing would remain essential. Integration would add appropriate services around the existing TB diagnostic pathway rather than replace accurate TB testing.

What are the main challenges of multi-disease testing?

Challenges include different sample requirements, test accuracy, equipment costs, staff training, quality assurance, regulatory requirements and ensuring that abnormal results lead to appropriate follow-up care.

Could integrated testing help rural patients?

It could. When several relevant services are coordinated during one visit, patients may have fewer reasons to travel repeatedly to distant healthcare facilities. The benefit depends on local diagnostic capacity and referral systems.

What is the most realistic future for integrated TB diagnostics?

The most realistic direction is likely to be connected diagnostic services in which several appropriate tests can be performed or coordinated during one visit, alongside selected multiplex platforms where technology and clinical evidence support their use.